News | Radiopharmaceuticals and Tracers | May 17, 2019

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent

Sixty-patient study will assess CellPoint’s Oncardia imaging agent for ability to evaluate presence, severity of coronary artery disease

New Phase 2B Trial Exploring Target-Specific Myocardial Ischemia Imaging Agent

May 17, 2019 — Biopharmaceutical company CellPoint plans to begin patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronary artery disease using the company's new one-vial Oncardia (ethylenedicysteine-glucosamine) kits.  The 60-patient trial study is being conducted in the U.S.

Today, slightly greater than 6 million nuclear cardiology perfusion imaging scans are performed in the U.S. annually. Such procedures, referred to as myocardial perfusion imaging (MPI), are performed using either single photon emission computed tomography (SPECT) or positron emission tomography (PET) camera systems. SPECT MPI procedures represent 98 percent of the total. All MPI procedures, regardless of the choice of radiopharmaceutical agent, are designed to illuminate the healthy perfused part of the heart. A high percentage of the patients are required to undergo a time-consuming rest and separate stress study. While there are several cardiovascular disease indicators that can be looked at with MPI, the predominant focus for such studies is the presence, location and severity of myocardial ischemia following a heart attack.  

99mTc-Oncardia is not a perfusion agent. It is being clinically studied as the first functional cardiovascular imaging agent that is target-specific for myocardial ischemia.  One of the clinical objectives of the study is to demonstrate that 99mTc-Oncardia can be effectively used where the patient does not need to be either physically or pharmacologically stressed for the study.

99mTc-Oncardia is for use with SPECT camera systems. CellPoint also is planning to clinically study 68Ga-Oncardia for use with PET camera systems.

For more information: www.cellpointweb.com

Related Content

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en
heart disease image
News | Cardiac Diagnostics | December 18, 2019
December 18, 2019 — In their latest report, “...
FDA Warns Troponin Tests Impacted by Biotin Dietary Supplement
Feature | Cardiac Diagnostics | November 05, 2019 | Dave Fornell, Editor
November 5, 2019 — The U.S.
Videos | Cardiac Diagnostics | October 29, 2019
Doctor Clyde Yancy was a keynote speaker and said doctors need to check their assumptions about patients at the door...
79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event

79-year-old Tony Marovic had a right carotid endarterectomy shortly after discovering a 95 percent blockage of his carotid artery at a health and wellness screening event. Image courtesy of University Hospitals.

News | Cardiac Diagnostics | October 16, 2019
Health and wellness screenings are more than just nice events for the community – they can save lives. A Mentor, Ohio,...
Pesticide Exposure May Increase Heart Disease and Stroke Risk

Image courtesy of zefe wu from Pixabay

News | Cardiac Diagnostics | October 15, 2019
On-the-job exposure to high levels of pesticides raised the risk of heart disease and stroke in a generally healthy...
World Heart Federation Launches Global Roadmap on Cardiovascular Disease Prevention Among Diabetics
News | Cardiac Diagnostics | September 04, 2019
At the European Society of Cardiology (ESC) Congress 2019 together with the World Congress of Cardiology, the World...